Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_3
3
50%
Ph phase_2
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

active_not_recruiting117%
completed583%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_2

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

NCT06283550
completedphase_3

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822
completedphase_2

Janus Kinase Inhibition in Sarcoidosis

NCT05696795
active_not_recruitingphase_2

Janus Kinase Inhibition in Granuloma Annulare

NCT05650736
completedphase_3

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

NCT05375929
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06283550Phase 2

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Completed
NCT03422822Phase 3

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed
NCT05696795Phase 2

Janus Kinase Inhibition in Sarcoidosis

Completed
NCT05650736Phase 2

Janus Kinase Inhibition in Granuloma Annulare

Active Not Recruiting
NCT05375929Phase 3

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Completed
NCT04345367Phase 3

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6